-+ 0.00%
-+ 0.00%
-+ 0.00%

The Zhitong Finance App learned that Amylyx Pharmaceuticals (AMLX.US) surged nearly 51% to $32.33 on Tuesday. According to the news, on August 18, Amylyx announced that its phase 3 Lucidity trial of the GLP-1 receptor antagonist avexitide to treat hypoglycemia PBH after weight loss surgery reached the main end. Compared with placebo, patients had a 55% reduction in grade 2 and grade 3 hypoglycemia events at week 16.

Zhitongcaijing·08/18/2026 15:25:02
Listen to the news
The Zhitong Finance App learned that Amylyx Pharmaceuticals (AMLX.US) surged nearly 51% to $32.33 on Tuesday. According to the news, on August 18, Amylyx announced that its phase 3 Lucidity trial of the GLP-1 receptor antagonist avexitide to treat hypoglycemia PBH after weight loss surgery reached the main end. Compared with placebo, patients had a 55% reduction in grade 2 and grade 3 hypoglycemia events at week 16.